Abstract
We argue that biological risk for novel inhibitory drug targets can be minimized, almost eliminated, by a computational analysis of the healthcare records and DNA sequences in resources like UK Biobank or All-of-Us. The key insight is that an inhibitory drug is functionally equivalent to a loss-of-function (LOF) variant in the targeted gene. It is a special case of what has been called an “experiment of nature”. To demonstrate, we considered all available clinical trials (58 in total) and inhibitory drugs (15 in total) for 5 cardiovascular drug targets: PCSK9, APOC3, ANGPTL3, LPA, and ASGR1. The results were shocking. Every biomarker assessed in these clinical trials was successfully predicted, i.e. directionality and proportionality of effect, but not the magnitude since that varies with dosage. This concept has not been widely adopted because geneticists believe that homozygous LOFs, which are exceedingly rare, would be needed to observe a significant phenotypic effect from most genetic knockouts. Our study shows that, to the contrary, given a sufficiently large biobank, counting both carriers and non-carriers, heterozygous LOFs alone can inform drug development.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding for this study was provided to ALS through the Natural Sciences and Engineering Research Council of Canada (NSERC) and the Canadian Research Chairs (CRC) program.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UK Biobank has approval from the North West Multi-Centre Research Ethics Committee as a Research Tissue Bank (RTB). This approval means that researchers do not require separate ethical clearance by their institution and can operate under the RTB approval. Our research was conducted under Application Number 85442.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
